Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.

Napoli R, Berra C, Catarig AM, Di Loreto C, Donatiello E, Berentzen TL, Pitocco D, Giorgino F

Diabetes, obesity & metabolism12 Mar 2023Cited by 26 (Europe PMC)

PMID36789682DOI10.1111/dom.15020PepBankPUB-36789682

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, mean HbA1c fell by 1.1%-point from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, HbA1c fell by 1.1 percentage points on weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n = 491
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1 %-point
effectiveness analysis set
Source sentences
Summary
In the EAS, mean HbA1c and body weight decreased by 1.1%-point (95% confidence interval 1.20, 1.05; P < .0001) and 4.2 kg (95% confidence interval 4.63, 3.67; P < .0001), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968201
02HumanObservational studySafety outcome
In adults with type 2 diabetes in routine practice, no new safety concerns were identified with once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, no new safety concerns were found with weekly semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSafety concerns
Study
n = 579
Outcome group
Adverse events · Whole body
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Source sentences
Summary
No new safety concerns were identified.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968208
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, mean body weight fell by 4.2 kg from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, body weight fell by 4.2 kg on weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline to end of study
Study
n = 491
Outcome group
Body weight · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
Body weight change
−4.2 kg
effectiveness analysis set
Source sentences
Summary
In the EAS, mean HbA1c and body weight decreased by 1.1%-point (95% confidence interval 1.20, 1.05; P < .0001) and 4.2 kg (95% confidence interval 4.63, 3.67; P < .0001), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968202
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, 61.7% reached HbA1c below 7.0% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, 61.7% reached an HbA1c below 7.0% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with HbA1c <7.0% at end of study
Study
n = 491
Outcome group
Glycemic control · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
61.7%
end of study
Source sentences
Summary
61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968203
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, 40.8% reached HbA1c below 6.5% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, 40.8% reached an HbA1c below 6.5% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with HbA1c <6.5% at end of study
Study
n = 491
Outcome group
Glycemic control · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <6.5%
40.8%
end of study
Source sentences
Summary
61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968204
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, 40.5% achieved weight loss of 5% or more at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, 40.5% lost 5% or more of body weight on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with weight loss of 5% or more
Study
n = 491
Outcome group
Body weight · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
Proportion weight loss >=5%
40.5%
end of study
Source sentences
Summary
40.5% achieved weight loss ≥5%
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968205
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, 25.3% achieved the post-hoc composite of HbA1c reduction of 1%-point or more and weight loss of 5% or more on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, 25.3% met a combined goal of lower HbA1c and weight loss on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion achieving composite endpoint (HbA1c reduction of 1%-point or more and weight loss of 5% or more)
Study
n = 491
Outcome group
Glycemic control · Metabolic and weight
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Measurements
Proportion composite endpoint
25.3%
end of study
Source sentences
Summary
25.3% achieved the post-hoc composite endpoint
2 context sentences(design, population, supporting numbers)
Summary · context
Other endpoints included changes in body weight, waist circumference and patient-reported outcomes, and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post-hoc composite endpoint (HbA1c reduction of ≥1%-point and weight loss ≥5%).
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968206
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, patient-reported outcomes improved from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, patient-reported outcomes improved on weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreasePatient-reported outcomes
Study
n = 491
Outcome group
Quality of life · Whole body
Studied dose
mean 0.66 mg at end of study (once weekly) · ~30 weeksAs given in this study (human).
Source sentences
Summary
Patient-reported outcomes improved from baseline to EOS.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled.
Report a problemFND-3678968207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04094415

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Novo Nordisk A/Sn = 58128 Oct 2019 to 28 Jul 2021

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 23 Feb 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.